Dianthus Therapeutics, Inc. (DNTH)
$77.58-4.89%Close
SELLCRISIS · day 15
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $3.2B
- Beta
- 0.08
- P/E (TTM)
- -596.77
- Short % float
- 31.35%
- Days to cover
- 8.3
- SI change
- +3.5%
- 1W
- -9.16%
- 1M
- -27.96%
- vs SPY 1W
- -9.02%
- vs SPY 1M
- -30.47%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
ANALYST & RATINGS
LOADING…Loading analyst data…
Company news
FAQ
- What is LOPJLB’s current signal on DNTH?
- LOPJLB’s latest quantitative signal on Dianthus Therapeutics, Inc. (DNTH) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is DNTH in?
- Dianthus Therapeutics, Inc. (DNTH) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Dianthus Therapeutics, Inc. (DNTH) do?
- Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of therapies for patients with severe autoimmune diseases. Its lead clinical-stage candidate, claseprubart, a monoclonal antibody engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein; and DNTH212, a bifunctional fusion protein that targ…